Recent Episodes
Watch recent episodes on
PTV News Review
Scroll Left
Scroll Right
Ganymed Pharma: Strategy for an Anticancer Antibody Therapeutics Company




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Ganymed Pharma: Strategy for an Anticancer Antibody Therapeutics Company
Released on: October 01, 2007. © PharmaVentures Ltd
Visitors: You are watching a 5 minute preview.
Get more information and subscribe now
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    In this exclusive interview, Fintan Walton talks to Rainer Wessel, CEO of Ganymed Pharma, about the formation of the company and the development of its antibody therapeutics.
  • Summary
  • Transcript
  • Participants
  • Company
In this exclusive interview, Fintan Walton talks to Rainer Wessel, CEO of Ganymed Pharma, about the formation of the company and the development of its antibody therapeutics. Dr Wessel discusses the company’s aim of creating products with blockbuster potential that will have an impact on the solid cancer antibody market, and the strategy through which it intends to achieve this. He describes the reasoning behind the April 2004 deal with Genmab in which Ganymed’s GT43 cancer target was out-licensed, as well as the possibility of forming partnerships for the company’s other products once they have shown proof-of-concept in man at Phase II/III, so that value has been created. In addition, Dr Wessel talks about the recent closing of Ganymed’s Series C financing round, plans to float the company in the future, and how acquisition approaches may be considered at some point if the offer is right. Finally, he briefly touches on the current state of biotech in Europe.
Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.
Rainer Wessel, PhD, is CEO of Ganymed Pharma. Before joining Ganymed in March 2004, Dr Wessel served at Axxima Pharmaceuticals as President and CEO. Before that, he was Head of IP and Licensing at Qiagen. Dr Wessel began his industry career at Boehringer Ingelheim, with which he served in Japan and Germany in positions of increasing responsibility. He is a member of the Board of BIO Deutschland, and of the Supervisory Board of ConoGenetix. He also serves as a Senior Advisor to the International Council for the Life Sciences (ICLS) in Washington, DC.
Ganymed Pharma